Swedish Orphan Biovitrum Stock Return On Asset

B6E Stock  EUR 26.86  0.00  0.00%   
Swedish Orphan Biovitrum fundamentals help investors to digest information that contributes to Swedish Orphan's financial success or failures. It also enables traders to predict the movement of Swedish Stock. The fundamental analysis module provides a way to measure Swedish Orphan's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Swedish Orphan stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Swedish Orphan Biovitrum Company Return On Asset Analysis

Swedish Orphan's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.

Return On Asset

 = 

Net Income

Total Assets

More About Return On Asset | All Equity Analysis

Current Swedish Orphan Return On Asset

    
  0.0555  
Most of Swedish Orphan's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Swedish Orphan Biovitrum is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
Competition

Based on the latest financial disclosure, Swedish Orphan Biovitrum has a Return On Asset of 0.0555. This is 100.63% lower than that of the Healthcare sector and 96.06% lower than that of the Drug Manufacturers - Specialty & Generic industry. The return on asset for all Germany stocks is 139.64% lower than that of the firm.

Swedish Return On Asset Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Swedish Orphan's direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Swedish Orphan could also be used in its relative valuation, which is a method of valuing Swedish Orphan by comparing valuation metrics of similar companies.
Swedish Orphan is rated third in return on asset category among its peers.

Swedish Fundamentals

About Swedish Orphan Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Swedish Orphan Biovitrum's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Swedish Orphan using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Swedish Orphan Biovitrum based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in Swedish Stock

Swedish Orphan financial ratios help investors to determine whether Swedish Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Swedish with respect to the benefits of owning Swedish Orphan security.